• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events

ASTMH 2011

4-8 December 2011

Philadelphia, USA

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi participated with presentations on the Leishmaniasis East Africa Platform and on Chagas disease, and also had several posters and a DNDi booth.

If you would like to download the Detailed Programme of DNDi attendance, please click here.

Presentations

“How regional platforms may facilitate innovation and access to new tools: The example of LEAP (Leishmaniasis East Africa) Platform” by Monique Wasunna, DNDi Africa/KEMRI
in the Symposium “A Decade Later: Drug Development and the Promise of Health Care Impact”

“Clinical trial of E1224 for treatment of Chagas disease” by Isabela Ribeiro, DNDi
in the Symposium “CYP51 as a Target for Chagas Disease Drugs”

Posters

“Analogues of fenarimol as novel compounds for the treatment of Chagas disease”
– AUTHORS: Martine Keenan [presenter],1 Mike Abbott,1 Paul Alexander,1 Tanya Armstrong,2 Wayne Best,1 Bradley Berven,1 Adriana Botero,2 Jason Chaplin,1 Susan Charman,3 Eric Chatelain,4 Hugo Diao,1 Tom von Geldern,4 Maria Kerfoot,2 Andrea Khong,2 Joshua McManus,1 Ivan Scandale,4 Andrew Thompson,2 Zhisen Wang,1 Karen White3
– AFFILIATIONS: 1. Epichem, Perth, Australia; 2. School of Veterinary & Biomedical Sciences, Murdoch University, Perth, Australia; 3. CDCO, Monash University, Melbourne, Australia; 4. Drugs for Neglected Diseases initiative, Geneva, Switzerland

“Flubendazole as a potential macrofilariacide for field use”
– AUTHORS: Charles MacKenzie,1 Timothy Geary,2 Nicole Madrill,1 Carlos Lanusse,3 Robert Don4
– AFFILIATIONS: 1. Michigan State University, East Lansing, MI, United States; 2. McGill University, Montreal, Canada; 3. Universidad Nacional del Centro, Tandil, Argentina; 4. Drugs for Neglected Diseases initiative, Geneva, Switzerland

“A systematic review and meta-analysis of non-randomized and randomized controlled studies of artesunate and amodiaquine for the treatment of uncomplicated falciparum malaria in Africa”
– AUTHORS: Piero L. Olliaro,1 Michel Vaillant,2 Michael O. Harhay3
– AFFILIATIONS: 1. World Health Organization (WHO), Geneva, Switzerland; 2. Santé, Luxembourg, Luxembourg; 3. University of Pennsylvania, Philadelphia, PA, United States

“Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection”
– AUTHORS: Zewdu H. Dadi,1 Workagegnehu Hailu,1 Teklu Weldegebreal,1 Hailemariam Tafes,2 Raymond Omollo,3 Sisay Yifru,1 Manica Balasegaram,4 Asrat Hailu5
– AFFILIATIONS: 1. University of Gondar, Gondar, Ethiopia; 2. Arbaminch Hospital, Arbaminch, Ethiopia; 3. Kenya Medical Research Institute (KEMRI), Nairobi, Kenya; 4. Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland; 5. Addis Ababa University, Addis Ababa, Ethiopia
In sub-Saharan Africa, visceral leishmaniasis (VL) is treated with either PentostamTM (sodium antimony gluconate) or generic sodium stibogluconate (SSG), except in Uganda where Glucantime® (meglumine antimoniate) has been in use for at least a decade. Between January 2008 and February 2009, 54 Ethiopian VL patients were treated with Glucantime. The medical charts of these patients were reviewed to assess the effectiveness and safety profile of Glucantime in a routine healthcare setting. None of the patients from south Ethiopia (n=24) and 46.4% of the patients from north Ethiopia (n=30) were HIV co-infected. At completion of treatment (Day 31), cure rates were 78.6% (95% CI 59.0-91.7%) in north Ethiopia and 100% (95% CI 85.8-100%) in south Ethiopia. Thirty-three non-serious and six serious adverse events (two pancreatitis, one renal failure and three deaths) were observed in 26 patients. One-third of the non-serious adverse events were due to biochemical pancreatitis. During treatment, a case-fatality rate of 10.0% in north Ethiopia and 0.0% in south Ethiopia was noted. These data show that Glucantime can be as effective as Pentostam or SSG in HIV-negative patients. The data also point to clinical pancreatitis as a safety concern, especially in patients with HIV co-infection. “Plasmodium falciparum polymorphisms and human CYP2C8 polymorphisms in clinical efficacy of artemisinin-based combination therapies in Liberia”
– AUTHORS: Sabina Dahlstrom,1 Vincent Jullien,2 Oumou Maiga-Ascofare,1 Birgit Schramm,3 Joel J. Jones,4 Yah M. Zolia,4 Elizabeth A. Ashley,3 Jean-Rene Kiechel,5 Philippe J. Guerin,3 Jacques Le Bras,6 Sandrine Houze7
– AFFILIATIONS: 1. Institut de Medecine et d’Epidemiologie Appliquee, Paris, France; 2. Saint-Vincent de Paul hospital, AP-HP, Paris, France; 3. Epicentre, Paris, France; 4. National Malaria Control Programme, Ministry of Health and Social Welfare, Monrovia, Liberia; 5. Drugs for Neglected Diseases initiative, Geneva, Switzerland; 6. Paris-Descartes University, IRD UMR216, Paris, France; 7. Parasitology Laboratory French National Malaria Reference Centre, AP-HP, Bichat-C. Bernard Hospital, Paris, France
Efficacy of artemisinin-based combination therapy in the treatment of uncomplicated malaria remains high in Africa, although treatment failures are not rare in clinical trials and reinfections are abundant in regions of high endemicity. Our aim was to understand genetic factors contributing to occurrence of recurrent infections by; 1) studying the selection of P. falciparum polymorphisms in pfcrt, pfmdr1 and pfmrp1 in patients treated with artesunate-amodiaquine (ASAQ) or artemether-lumefantrine (AL) and 2) assessing whether malaria patients with polymorphisms in CYP2C8, the major enzyme in the metabolization of amodiaquine (AQ) to its active metabolite monodesethylamodiaquine (DEAQ), have lower blood concentration of DEAQ after ASAQ treatment. P. falciparum infected patients from a clinical efficacy trial comparing fixed dose ASAQ (n=150) with AL (n=150) and from the ASAQ arm (n=498) of a tolerability trial conducted in Saclepea Comprehensive Health Center in Nimba county, Liberia, were analysed. In the efficacy trial parasite molecular markers pfcrt K76T, pfmdr1 N86Y, Y184F, D1246Y and pfmrp1 I876V and K1466R were assessed in pre- and post-treatment blood samples. The three main polymorphisms of CYP2C8, *2, *3 and *4, were analysed in patients treated with ASAQ. Pfmdr1 1246Y was observed to be selected in reinfections in the ASAQ arm and pfcrt K76 and pfmdr1 N86 were selected in AL reinfections. Reinfections carrying pfmdr1 1246Y and pfmdr1 N86 was observed to occur early, in the ASAQ and the AL arm respectively. A substantial prevalence of CYP2C8*2 (29%) was observed, whereas the *4 and *3 polymorphisms were detected rarely or not at all. In the efficacy trial patients with CYP2C8*2 polymorphisms had a slightly lower, concentration of DEAQ at day 7, however not reaching statistical significance. This trend was not seen in the tolerability trial. CYP2C8*2 was not a significant risk factor for treatment failure or reinfection after ASAQ treatment. Selection of reinfecting parasites may indicate tolerance, a first step in the process towards full drug resistance.

Blog

Anatomy of projects: PDP lessons
December 6, 2011
By John Donnelly

A decade ago, many global health experts trying to develop new drugs, vaccines, or diagnostic tools admitted they had a market failure. Industry dropped projects because they couldn’t be assured of making a profit. Researching solutions for diseases affecting mainly the poor started to dry up.

The crisis led to the formation of several groups called Product Development Partnerships, or PDPs. They were tasked to hunt for promising research, possible players, and funders, under the theory that together the actors could produce a breakthrough unattainable to a group working alone.

In a session Tuesday at the ASTMH annual meeting in Philadelphia, representatives from PDPs; biotech and pharmaceutical companies; NGOs; and the World Health Organization talked about successes from the collaborations – as well as suggestions on ways to improve the model.

Dr. Robert D. Newman, director of Global Malaria Programme at WHO, said that PDPs such as Medicines for Malaria Venture (MMV), the Foundation for Innovative New Diagnostics, and the Malaria Vaccine Initiative have been invaluable. “From the seat I sit in, there is an array of PDPs that have been essential to the progress we have made and we will need in the future,” he said.

He said it was urgent to produce new malaria drugs given the findings of resistance to artemisinin along the Cambodia-Thailand border, a development that malaria experts believe is likely the start of an eventual spread of resistance around the world.

“We need to be working on new medicines,” Newman said. “But without PDPs, we would not have this pipeline (for drugs and vaccines) we have in place today.”
Two representatives of industry — Dr. Yves Ribeill, CEO of SCYNEXIS, a Durham, N.C.-based biotech firm, and Silvio C. Gabriel, executive vice president and head of Malaria Initiatives at Novartis Pharma – said their PDP experiences were fruitful but they also suggested improvements.

Both teamed with multiple partners – SCYNEXIS on a drug candidate for Human African Trypanosomiasis, or sleeping sickness, and Novartis on several malaria drugs, including a pediatric formulation.

Ribeill said that 50 percent of new drugs for neglected diseases were the result of biotech innovation and “if we want to make a greater impact, biotechs can play a very strong role.”

The sleeping sickness project, which was managed by Drugs for Neglected Diseases initiative, needed many pieces to come together, he said. It required $15 million in funding over three years; a partner, Anacor, to provide technology due to a “very motivated CEO;” and his motivation and those of scientists at SCYNEXIS, including “some who asked not to be taken off the project and if they had to leave it, they said they were willing to work for free.” In all, he said, 19 people were working on the project, which has produced a drug candidate that will enter clinical trials next year.

Novartis’ Gabriel said pharmaceutical companies needed to make clear-eyed assessments about the economics of a project as well as how it would affect the company reputation. In the end, his collaboration with MMV and others produced more than 400 million treatments of malaria medication. That was his bottom line, he said, but he added that Novartis did not make money on the venture and at the beginning it absorbed a reputational hit when Doctors Without Borders led a protest that Novartis was not producing more malaria drugs.

The truth, he said, was that it took 14 months to produce the drugs from the manufacturer, and Novartis was given a 12-month deadline. Other issues, he said, was the poor forecasting on the need for malaria drugs. In 2005, for instance, Novartis was asked to produce 30 million treatments but only 9 million were used.

His lessons: the project should plan not just research and development but also include what is best for the patient; support from a company CEO was essential; partners need to share the same values; all have to contribute; and a “great team is needed.”

“For me, this was the most fascinating job I ever did,” Gabriel said. “For my personal life, this was the best experience I ever had.”

Other events

Loading...
13-14 March 2023

Putrajaya, Malaysia

Tropical Infectious Diseases Conference 2023

6 February 2023, 5 PM Madrid

Madrid, Spain and online

La Salud Global y las Enfermedades Tropicales Desatendidas en su día mundial

30 January 2023, 5-8 PM Hamburg

Hamburg, Germany

World NTD Day 2023: Snack & Talk about NTDs

29 January 2023

Referral Hospital, Baniapur, Saran, Bihar

Honouring frontline heroes of NTDs

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo